Evaluation of Prevalence of Side-Effects Associated with Booster Dose of mRNA-Based COVID-19 Vaccine Among Healthcare Workers in Eastern Province, Saudi Arabia: A Descriptive Cross-Sectional Study

References

• World Health Organization. Global coronavirus statistics. United Nations. Available from: https://covid19.who.int/region/amro/country/us. Accessed May 9, 2022.
   Google Scholar
• Coronavirus cases. Reported cases and deaths by country or territory. Available from: https://www.worldometers.info/coronavirus/#countries. Accessed May 9, 2022.
   Google Scholar
• Global Situation. WHO coronavirus (COVID-19) dashboard global situation. Available from: https://covid19.who.int/?mapFilter=cases. Accessed May 9, 2022.
   Google Scholar
• FDA; 2021 [ updated March 11, 2022]. FDA Approves First COVID-19 Vaccine. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine. Accessed May 9, 2022.
   Google Scholar
• Ministry of Health. COVID‐19 & vaccine FAQs. Riyadh: Ministry of Health; 2021. Available from: https://www.moh.gov.sa/en/Ministry/HotTopics/Pages/COVID‐19‐Vaccine.aspx. Accessed January 5, 2022.
   Google Scholar
• Two more COVID-19 vaccines approved for use in Saudi Arabia. Available from: https://www.arabnews.com/node/1794826/saudi-arabia. Accessed January 5, 2022.
   Google Scholar
• Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19. Available from: https://apps.who.int/iris/rest/bitstreams/1327316/retrieve. Accessed January 5, 2022.
   Google Scholar
• Interim statement on booster doses for COVID-19 vaccination. Available from: https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination—update-22-december-2021. Accessed January 5, 2022.
   Google Scholar
• News. Available from: https://sfda.gov.sa/en/cnews. Accessed January 5, 2022.
   Google Scholar
• Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–1090. doi:10.1056/NEJMoa2110475
   PubMed Web of Science ®Google Scholar
• AHelping latinos recover and thrive. Available from: https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination—update-22-december-2021. Accessed May 9, 2022.
   Google Scholar
• Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1428. doi:10.3390/jcm10071428
   PubMed Web of Science ®Google Scholar
• Alrajeh AM, Daghash H, Buanz SF, Altharman HA, Belal S. COVID-19 vaccine hesitancy among the adult population in Saudi Arabia. Cureus. 2021;13(12):e20197. doi:10.7759/cureus.20197
   Web of Science ®Google Scholar
• Kaur RJ, Dutta S, Bhardwaj P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):427–439. doi:10.1007/s12291-021-00968-z
   PubMed Web of Science ®Google Scholar
• Abu-Halaweh S, Alqassieh R, Suleiman A, et al. Qualitative assessment of early adverse effects of pfizer-BioNTech and sinopharm COVID-19 vaccines by telephone interviews. Vaccines. 2021;9(9):950. doi:10.3390/vaccines9090950
   Web of Science ®Google Scholar
• Klugar M, Riad A, Mekhemar M, et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. Biology. 2021;10(8):752. doi:10.3390/biology10080752
   PubMed Web of Science ®Google Scholar
• Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939–949. doi:10.1016/S1473-3099(21)00224-3
   PubMed Web of Science ®Google Scholar
• Saeed BQ, Al‐Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID‐19 vaccination. Int J Infect Dis. 2021;111:219–226. doi:10.1016/j.ijid.2021.08.013
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine through 6 months. N Engl J Med. 2021;385:1761–1773. doi:10.1056/NEJMoa2110345
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–593. doi:10.1038/s41586-020-2639-4
   PubMed Web of Science ®Google Scholar
• Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. Eur J Hosp Pharm. 2021;ejhpharm-2021-002933. doi:10.1136/ejhpharm-2021-002933
   Google Scholar
• Arce JSS, Warren SS, Meriggi NF, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. 2021;27(8):1385–1394. doi:10.1038/s41591-021-01454-y
   PubMed Web of Science ®Google Scholar
• Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9(4):1423–1437. doi:10.1016/j.jaip.2020.12.04
   PubMed Web of Science ®Google Scholar
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Available from: https://www.equator-network.org/reporting-guidelines/strobe/. Accessed June 18, 2022.
   Google Scholar
• Lwanga SK, Lemeshow S; World Health Organization. Sample Size Determination in Health Studies: A Practical Manual. Geneva, Switzerland:World Health Organization; 1991. Available from: https://apps.who.int/iris/handle/10665/40062. Accessed February 10, 2022.
   Google Scholar
• Israel, G.D. Determining sample size; technical report. Gainesville, FL, USA: University of Florida; 1992. Available from: https://www.tarleton.edu/academicassessment/documents/samplesize.pdf. Accessed February 10, 2022.
   Google Scholar
• Cuschieri S, Borg M, Agius S, Souness J, Brincat A, Grech V. Adverse reactions to Pfizer-BioNTech vaccination of healthcare workers at Malta’s state hospital. Int J Clin Pract. 2021;75:e14605. doi:10.1111/ijcp.14605
   Web of Science ®Google Scholar
• Hagin D, Freund T, Navon M, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021;148:739–749. doi:10.1016/j.jaci.2021.05.029
   PubMed Web of Science ®Google Scholar
• Nittner-Marszalska M, Rosiek-Biegus M, Kope´c A, et al. Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals. Vaccines. 2021;9:553. doi:10.3390/vaccines9060553
   Web of Science ®Google Scholar
• Bendel RB, Afifi AA. Comparison of stopping rules in forward “stepwise” regression. J Am Stat Assoc. 1977;72:46–53.
   Web of Science ®Google Scholar
• Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70.
   Web of Science ®Google Scholar
• Munro APS, Janani L, Cornelius V. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, Phase 2 trial. Lancet. 2021;398(10318):2258–2276. doi:10.1016/S0140-6736(21)02717-3
   PubMed Web of Science ®Google Scholar
• Alhazmi A, Alamer E, Daws D, et al. Evaluation of side‐effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines. 2021;9(6):674. doi:10.3390/vaccines9060674
   PubMed Web of Science ®Google Scholar
• Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021;384:1576–1577. doi:10.1056/NEJMc2036242
   PubMed Web of Science ®Google Scholar
• Edelman A, Boniface ER, Benhar E, et al. Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a US cohort. Obstet Gynecol. 2022;139(4):481–489. doi:10.1097/AOG.0000000000004695
   Web of Science ®Google Scholar
• McCartney PR. Sex-based vaccine response in the context of COVID-19. J Obstet Gynecol Neonatal Nurs. 2020;49(5):405–408. doi:10.1016/j.jogn.2020.08.001
   Web of Science ®Google Scholar
• Vassallo A, Shajahan S, Harris K, et al. Sex and gender in COVID-19 vaccine research: substantial evidence gaps remain. Front Glob Womens Health. 2021;2:761511. doi:10.3389/fgwh.2021.761511
   Google Scholar
• Harris T, Nair J, Fediurek J, Deeks SL. Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012–2015. Vaccine. 2017;35(19):2600–2604. doi:10.1016/j.vaccine.2017.03.035
   Web of Science ®Google Scholar
• Darraj MA, Al-Mekhlafi HM. Prospective evaluation of side-effects following the first dose of Oxford/AstraZeneca COVID-19 vaccine among healthcare workers in Saudi Arabia. Vaccines. 2022;10(2):223. doi:10.3390/vaccines10020223
   Web of Science ®Google Scholar
• Lv M, Luo X, Shen Q, et al. Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: a systematic review. Vaccines. 2021;9(10):1102. doi:10.3390/vaccines9101102
   Web of Science ®Google Scholar
• Loosen SH, Bohlken J, Weber K, et al. Factors associated with non-severe adverse reactions after vaccination against SARS-CoV-2: a Cohort Study of 908,869 outpatient vaccinations in Germany. Vaccines. 2022;10(4):566. doi:10.3390/vaccines10040566
   Web of Science ®Google Scholar
• Alghamdi AA, Alkazemi A, Alissa A, Alghamdi I, Alwarafi G, Waggas HA. Adverse events following AstraZeneca COVID-19 vaccine in Saudi Arabia: a cross-sectional study among healthcare and nonhealthcare workers. Intervirology. 2022;65(2):104–109. doi:10.1159/000519456
   PubMed Web of Science ®Google Scholar
• Adam M, Gameraddin M, Alelyani M, et al. Evaluation of post‐vaccination symptoms of two common COVID‐19 vaccines used in Abha, Aseer Region, Kingdom of Saudi Arabia. Patient Prefer Adherence. 2021;15:1963–1970. doi:10.2147/PPA.S330689
   Web of Science ®Google Scholar
• Kałucka S, Kusideł E, Głowacka A, Oczoś P, Grzegorczyk-Karolak I. Pre-vaccination stress, post-vaccination adverse reactions, and attitudes towards vaccination after receiving the COVID-19 vaccine among health care workers. Vaccines. 2022;10(3):401. doi:10.3390/vaccines10030401
   Web of Science ®Google Scholar
• Dionne A, Sperotto F, Chamberlain S, et al. Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. JAMA Cardiol. 2021;6(12):1446–1450. doi:10.1001/jamacardio.2021.3471
   PubMed Web of Science ®Google Scholar